An observational study in Chronic Hepatitis c, sponsored by Tongji Hospital. Status unknown. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-05-08.
Sponsored by Tongji Hospital · Observational
To evaluate the efficacy, adverse effect, short - and long-term outcomes of Glecaprevir/Pibrentasvir for the treatment of chronic hepatitis C (non-cirrhotic or compensatory cirrhosis)in China through a real-world study
This study is a multi-center, prospective, real-world study, aiming to investigate the use of Glecaprevir/Pibrentasvir in routine clinical management of chronic hepatitis C patients and evaluate its effectiveness and safety across a heterogeneous population in China.Approximately 800 patients will take part in this study, 20 sites will be included which distribute in China's major cities, thus each site will enroll 40 patients.
2,321 studies on the registry are indexed under Hepatitis C; 102 are open to participants now.
This study's planned enrollment of 800 is above the median of 244 across 567 observational studies indexed under Hepatitis C.
Browse Hepatitis C studies →Tongji Hospital is the lead sponsor of 373 studies on the registry; 204 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with chronic hepatitis C who will received Glecaprevir/Pibrentasvir treatment and meet the inclusion and exclusion criteria above
Exclusion Criteria:
Chronic hepatitis C patients who will recieve Glecaprevir/Pibrentasvir treatment
Drug: Glecaprevir/Pibrentasvir
Chronic hepatitis C patients will be given Glecaprevir/Pibrentasvir treatment
Also known as: Mavyret
SVR 12
The effectiveness of Glecaprevir/Pibrentasvir treatments and SVR rate 12 weeks after Glecaprevir/Pibrentasvir treatments
Time frame: 12 weeks after Glecaprevir/Pibrentasvir treatments
progression of Chronic liver disease
Incidence of liver disease progression (such as cirrhosis, decompensation of liver function, liver cancer, liver transplantation, or liver related death)
Time frame: 5 years after Glecaprevir/Pibrentasvir treatments
long term outcome
Assess the duration of the virologic response (5 years) in CHC patients with daas-based regimens who have achieved a sustained virologic response (svr12/24) at 12 or 24 weeks after the end of treatment and analyze the factors influencing the recurrence of HCV
Time frame: 5 years
HRQOL
To evaluate the impact of DAAs treatment on health-related quality of life (HRQOL) and health status of CHC patients
Time frame: 5 years
No study locations are listed for this record.
This study is status unknown, as verified in May 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tongji Hospital